Loading stock data…
Sera Prognostics, Inc. (SERA)
$2.01-0.01 (-0.50%)
Market ClosedLast close Sep 8
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sera Prognostics, Inc. in the Healthcare sector is trading at $2.01 with a market capitalization of $80M. Wall Street consensus targets $5.50 (2 analysts), implying a +173.6% move over the next 12 months. The stock is currently near its 52-week low of $1.56, remaining 15.2% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +173.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $14,000↑ | $10,000↓ | $16,000↓ | $17,000↓ | $38,000 |
| Gross Profit | -$28,000↑ | -$32,000↓ | -$25,000↓ | -$24,000↓ | -$2,000 |
| Operating Income | -$9.36M↓ | -$8.95M↑ | -$8.98M↑ | -$9.32M↓ | -$9.25M |
| Net Income | -$8.40M↓ | -$7.88M↓ | -$7.81M↑ | -$8.05M↑ | -$8.19M |
Peer Comparison
JNJUNHPFE
Fundamentals
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$80.28M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.93
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-47.53%
Volume
Today's trading volume
64,073
Recent News
Sera (SERA) Q2 2026 Earnings Call Transcript
Illinois Medicaid coverage for PreTRM test unlocks 50,000 annual births as payer access expands.
Sera Prognostics, Inc. Q2 2026 Earnings Call Summary
Moby summary of Sera Prognostics, Inc.'s Q2 2026 earnings call
Sera Prognostics Inc (SERA) (Q2 2026) Earnings Call Highlights: Payer Momentum Builds with ...
Despite minimal revenue, Sera Prognostics advances commercial strategy with new payer programs and a strengthened cash runway through 2029.
Sera Prognostics Q2 Earnings Call Highlights
Sera Prognostics (NASDAQ:SERA) reported modest second-quarter revenue while outlining progress in payer engagement, Illinois Medicaid policy, clinical evidence and European regulatory preparations for its PreTRM Test-guided care platform. Revenue for the quarter ended June 30 was $30,000, compared
Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Misses Revenue Estimates
Sera Prognostics (SERA) delivered earnings and revenue surprises of -28.57% and -76.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?